Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
Philip SambrookUniversity of Sydney, SydneyAbstract: Osteoporosis is a chronic condition that generally requires long-term therapy for fracture risk reduction to become apparent. Although the bisphosphonates have made a major contribution to how clinicians manage osteoporosis, compliance with therap...
Enregistré dans:
| Auteur principal: | Philip Sambrook |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2007
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/278f4da4b1c54daf85c4234cf9946289 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
par: Esteban Jódar-Gimeno
Publié: (2007) -
Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice
par: Oliver Bock, et autres
Publié: (2008) -
Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
par: John Sunyecz
Publié: (2008) -
Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
par: María J Moro-Álvarez, et autres
Publié: (2008) -
The effect of a combined oral calcium and vitamin D supplement for treating mild to moderate vitamin D deficiency in postmenopausal women
par: Terry Golombick, et autres
Publié: (2008)